We are thrilled to announce the publication of our study, “Humanized anti-BAMBI monoclonal antibody as a novel therapeutic strategy for psoriatic arthritis”, in Journal of...

Inhibitec has received funding ((€3,533.45) through the Planes de Promoción Comercial program (NM25-PC-109), supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN). This grant...

Inhibitec Antibodies has been selected for the ‘Programa Personal Técnico I+D’, supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN), enabling us to expand...

Inhibitec Antibodies has been one of the startups selected in the ‘Programa Personal Tecnico I+D’ supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN)...

Towards a new therapy in psoriasis and psoriatic arthritis Inhibitec Anticuerpos S.L. has been selected as a recipient of the grant CPP2022-009666, supporting the development...

Inhibitec is selected as finalist in the BIO-Europe Spring Startup Spotlight competition. This exciting competition offers entrepreneurs an affordable opportunity to engage with top-tier investors...